Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Glossary Glossary
The Body Covers: The First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Session 5: Recent Cohort Studies

June 27, 1999

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Looking at cross-sectional data from Sydney, this presentation examined a syndrome of lipodystrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase (NRTI) therapy and its contribution to PI-related lipodystrophy syndrome. The data included 102 patients with lipodystrophy on HAART including PIs. However, of interest was the new report of 14 patients who also reported loss of fat from arms, legs and face, yet were taking only NRTIs, including d4T, ddI, 3TC, AZT, one-fifth of which were on non-nucleoside RTIs (NNRTIs). In contrast to patients developing lipodystrophy on PI containing regimen, these 14 patients were characterized by recent onset fatigue, nausea, mean weight loss of 6 kg over 4 months, abdominal distension (hepatomegaly without ascites), elevated serum lactate levels (1.4 vs. 4.6 mmol/L, respectively), and liver enzymes. In addition, these 14 patients developing body fat changes on NRTIs had low serum albumin concentrations and did not have hypertriglyceridemia. Metabolic alterations reportedly improved after cessation of NRTIs but weight gain was limited.

Among patients on NRTIs, the duration of therapy, d4T use and serum lactate levels were associated with body fat changes. Thus, HIV-infected patients who developed body fat changes on NRTIs had a syndrome that is distinguishable from the lipodystrophy syndrome developing with PI-containing HAART use. Constitutional symptoms, lactic acidemia and hepatic dysfunction and recent weight loss characterize the syndrome with NRTI use. However, because significant weight loss occurred in these patients with NRTI use, it appears that this study cannot rule out wasting as a cause of the observed body fat loss.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Abstract: Sydney Cohort
Authored by: A. Carr

See Also
An HIVer's Guide to Metabolic Complications
More Research on Lipodystrophy and Other Metabolic Complications



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement